CL Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Colgate-Palmolive delivered a stronger-than-expected fourth quarter, posting non-GAAP Base Business EPS of $0.95 against a consensus estimate of $0.91, a beat of 4.40%, while revenue of $5.23 billion topped the $5.13 billion estimate and rose 5.8% ye… Read more Colgate-Palmolive delivered a stronger-than-expected fourth quarter, posting non-GAAP Base Business EPS of $0.95 against a consensus estimate of $0.91, a beat of 4.40%, while revenue of $5.23 billion topped the $5.13 billion estimate and rose 5.8% year over year. The headline results masked significant noise beneath the surface, as a $919 million pre-tax goodwill impairment charge tied to its Filorga skin health business, hurt by sluggish category growth and weakness in China, swung GAAP EPS to a loss of $0.05 per share. Operational resilience carried the non-GAAP story, with organic sales growth of 2.2% and a meaningful 3.1% tailwind from foreign exchange lifting reported sales. Africa/Eurasia led divisional performance at 10.3% organic growth, while North America slipped 1.8%. Looking ahead, management guided 2026 net sales growth of 2% to 6% and low-to-mid-single-digit Base Business EPS growth, while unveiling a new 2030 strategy centered on AI-driven analytics and science-based innovation. The company also extended its streak of consecutive annual dividend increases to 63 years, reinforcing its Dividend Aristocrat credentials.